Maintenance therapy with pazopanib after successful initial chemotherapy for advanced ovarian cancer prolongs time to relapse and PFS compared to placebo, found research presented at ASCO 2013.
In patients with melaoma at high risk of recurrence, adjuvant bevacizumab is well tolerated and improves the disease-free interval, found research presented at ASCO 2013.
Combined anti-HER2 therapy, with or without chemotherapy, does not increase the risk for cardiac toxicities compared to anti-HER2 monotherapy, found research presented at ASCO 2013.
A survey found that 83% of U.S. oncologists/hematologists reported a chemo drug shortage in the past 6 months, with 94% stating patient care was affected, according to data presented at ASCO 2013.
In men with localized high-risk prostate cancer, androgen-deprivation therapy can be safely reduced from 36 to 18 months, according to research presented at ASCO 2013.
Women with uterine malignancies who took statins and aspirin had an 84% reduction in mortality, while use of statins alone reduced mortality by 45%, according to data presented at ASCO 2013.
MPDL3280A produced durable responses in patients with locally advanced or metastatic lung cancer, melanoma, and renal, colorectal, and gastric cancers, some within days of treatment initiation, found research at ASCO 2013.
Nintedanib in combination with docetaxel significantly prolonged PFS for patients with metastatic NSCLC progressing after first-line chemotherapy regardless of histology, results from the LUME-Lung 1 trial presented at ASCO 2013 have found.
The number of genetic alterations in tumors may predict which patients with breast cancer will benefit from adding everolimus to exemestane, found research presented at ASCO 2013.
VeriStrat test status predicts which patients will see survival benefits from second-line chemotherapy instead of erlotinib therapy for advanced NSCLC, found data presented at ASCO 2013.
Standard-dose radiation therapy is superior to high-dose RT in terms of OS and local-regional control in patients undergoing chemotherapy for stage III NSCLC, found research presented at ASCO 2013.
Imatinib is prolongs PFS but not OS compared to placebo among patients with imatinib- or sunitinib-refractory advanced GIST, according to data presented at ASCO 2013.
Idelalisib (GS-1101) is associated with rapid tumor response in some patients diagnosed with relapsed or treatment-resistant CLL, found research presented at ASCO 2013.
Elderly patients with metastatic pancreatic cancer have shorter OS and receive less chemotherapy, fewer agents compared to younger patients, found research presented at ASCO 2013.
NGS shows promise in identifying solid tumors harboring "actionable" genetic alterations that can be targeted for personalized therapy, according to study results presented at ASCO 2013.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Immunotherapy and the Future of Prostate Cancer Treatment
- Explaining Androgen Receptor-indifferent Prostate Cancer
- Dual Immunotherapy Active vs Sunitinib for PD-L1+ Advanced RCC
- 2017 ASCO GU Symposium: Updates in Managing Small Renal Masses
- First-line Immune Checkpoint Inhibition Cost-effective in Melanoma